Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pabinafusp alfa - JCR Pharmaceuticals

Next Previous
Drug Profile

Pabinafusp alfa - JCR Pharmaceuticals

Alternative Names: IZCARGO; JR 141; Recombinant iduronate-2-sulfatase - JCR Pharmaceuticals; TAK-141

Latest Information Update: 10 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator JCR Pharmaceuticals
  • Class Antibodies; Iduronate sulfatases; Recombinant fusion proteins
  • Mechanism of Action Iduronate sulfatase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis II
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Mucopolysaccharidosis II

Most Recent Events

  • 30 Jun 2024 Takeda and JCR enters into an agreement ending the geographically-focused exclusive collaboration and license agreement to commercialize pabinafusp alfa in Mucopolysaccharidosis-II (Takeda Pipeline, February 2025)
  • 06 Apr 2023 JCR Pharmaceuticals and Sumitomo Pharma agree to co-promote pabinafusp alfa in Japan for Mucopolysaccharidosis-II
  • 27 Mar 2023 Pabinafusp alfa is available on a Named Patient Access Programme for the treatment of Mucopolysaccharidosis II in countries where it is not commercially available

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top